The FDA improperly authorized Zyn nicotine pouches without adequate safety review.

Some argue that the FDA's authorization of Zyn nicotine pouches lacked a thorough safety evaluation, raising concerns about public health. Others believe that the agency followed appropriate protocols and that the pouches are safe for consumer use. The debate centers on the adequacy of the FDA's review process and the implications for regulatory practices.